Cytek Biosciences, Inc. (CTKB) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Cytek Biosciences, Inc. (CTKB) Earnings Overview
As of June 24, 2026, Cytek Biosciences, Inc. (CTKB) reported trailing twelve-month net income of -$74M, reflecting -1028.0% year-over-year growth. The company earned $-0.57 per diluted share over the past four quarters, with a net profit margin of -33.0%.
Looking at the long-term picture, CTKB's historical earnings data spans multiple years. The company achieved its highest annual net income of $19M in fiscal 2020.
Cytek Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ILMN ($853M net income, 19.6% margin), HOLX ($544M net income, 13.8% margin), AZTA (-$178M net income, -9.4% margin), CTKB has room to improve margins relative to the peer group. Compare CTKB vs ILMN →
CTKB Earnings vs Peers
Earnings metrics vs comparable public companies
CTKB Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$67M | -1005.3% | -$40M | $-0.52 | -33.0% | -20.0% |
| 2024 | -$6M | +50.4% | -$21M | $-0.05 | -3.0% | -10.2% |
| 2023 | -$12M | -571.6% | -$28M | $-0.09 | -6.3% | -14.4% |
| 2022 | $3M | -14.2% | -$2M | $0.02 | 1.6% | -1.1% |
| 2021 | $3M | -84.5% | $9M | $0.03 | 2.3% | 7.2% |
| 2020 | $19M | +215.4% | $14M | $0.02 | 20.9% | 14.7% |
| 2019 | -$17M | - | -$17M | $-0.13 | -29.1% | -29.8% |
Download Data
Export CTKB earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CTKB — Frequently Asked Questions
Quick answers to the most common questions about buying CTKB stock.
What is CTKB earnings per share (EPS)?
CTKB trailing twelve-month (TTM) diluted EPS is $-0.57, reflecting -1028.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Cytek Biosciences, Inc.'s net income?
Cytek Biosciences, Inc. (CTKB) trailing twelve-month net income is $-74M as of 2025. Earnings declined -1028.0% year-over-year.
Is CTKB profitable?
CTKB is not currently profitable on a TTM basis, reporting a net loss of $-74M. Net margin is -33.0%. Investors should monitor for a return to profitability.
What is CTKB's earnings growth rate?
CTKB compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are CTKB's profit margins?
Cytek Biosciences, Inc. net profit margin is -33.0%, operating margin is -20.0%, and gross margin is +51.8%. Below-average margins reflect competitive or cost pressures. Return on Equity is -18.0%.
Is CTKB growing earnings?
CTKB earnings are declining — EPS fell -1028.0% year-over-year. TTM net income dropped to $-74M. This contrasts with the 5-year CAGR of N/A.
What was CTKB's best earnings year?
Cytek Biosciences, Inc.'s highest annual net income on record is $19M, achieved in fiscal year 2020. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were CTKB's earnings last quarter?
CTKB's most recent reported quarter was Q1 2026. Net income was $-19M with diluted EPS of $-0.15. For a full breakdown of all quarters, see the quarterly earnings table on this page.